EugeniaGirdaMD

Obstetrics & Gynecology • New Brunswick, NJ

Gynecologic Oncology

Gynecologic Oncology

Join to view full profile

Dr. Girda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Girda's full profile

Already have an account?

Office
195 Little Albany St
New Brunswick, NJ 08901
Phone+1 732-235-7258

Education & Training

Montefiore Medical Center/Albert Einstein College of MedicineResidency, Obstetrics and Gynecology, 2010 - 2014
Stony Brook University Health Sciences Center School of MedicineClass of 2010
University of California Davis HealthFellowship, Gynecologic Oncology

Certifications & Licensure

CA State Medical License 2014 - Present
NJ State Medical License 2017 - 2025
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Clinical Trials

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies Start of enrollment: 2014 Oct 27
Completed
Phase 1
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Start of enrollment: 2015 Dec 18
RECRUITING
PHASE2
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2016 Oct 31
Completed
Phase 1, Phase 2
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors Start of enrollment: 2016 Nov 15
Completed
Phase 1
Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer Start of enrollment: 2017 Mar 10
Active, not recruiting
Phase 1
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Start of enrollment: 2017 Oct 09
Completed
Phase 1, Phase 2
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2018 Oct 12
ACTIVE_NOT_RECRUITING
PHASE2
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol Start of enrollment: 2020 Jan 15
RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).
Husam A Alqaisi, David E Cohn, Jing-Yi Chern, Linda R Duska, Andrea Jewell
Clinical Cancer Research. 2025-03-17
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.
Wafik S El-Deiry, Catherine Bresson, Fanny Wunder, Benedito A Carneiro, Don S Dizon
Oncotarget. 2025-03-12
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope
Nature Medicine. 2025-03-05

Lectures

An open-label phase 1 trial of the safety and efficacy of daily subcutaneous SPL-108 injections when used in combination with paclitaxel in patients with platinum-resi...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Splash Pharmaceuticals Announces Clinical Trial Presentation at the 2018 American Society of Clinical Oncology Annual MeetingMay 29th, 2018
Experts Address the Latest on Cervical Cancer TreatmentJanuary 26th, 2024

Professional Memberships

Socitey of Gynecologic Oncology
Member

Other Languages

Russian